145 related articles for article (PubMed ID: 6931828)
1. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
[TBL] [Abstract][Full Text] [Related]
2. Isolation, drug sensitivity, and some biochemical and genetical properties of macromomycin-resistant mouse lymphoblastoma L5178Y cells.
Suzuki H; Sugimoto Y; Tanaka K; Nishimura T; Tanaka N
J Antibiot (Tokyo); 1984 May; 37(5):602-9. PubMed ID: 6547433
[TBL] [Abstract][Full Text] [Related]
3. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of 2-crotonyloxymethyl-4,5,6-trihydroxycyclohex-2-enone, a SH inhibitory antitumor antibiotic, and its effect on drug-resistant neoplastic cells.
Sugimoto Y; Suzuki H; Yamaki H; Nishimura T; Tanaka N
J Antibiot (Tokyo); 1982 Sep; 35(9):1222-30. PubMed ID: 7142023
[TBL] [Abstract][Full Text] [Related]
5. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
Tanaka N
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
[TBL] [Abstract][Full Text] [Related]
6. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
Tanaka N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of adriamycin resistance in a subline of mouse lymphoblastoma L5178Y cells.
Nishimura T; Suzuki H; Muto K; Tanaka N
J Antibiot (Tokyo); 1979 May; 32(5):518-22. PubMed ID: 583339
[TBL] [Abstract][Full Text] [Related]
8. Alteration of membrane-associated enzymes in drug-resistant sublines of mouse lymphoblastoma L5178Y cells.
Sugimoto Y; Nishimura T; Suzuki H; Tanaka N
J Antibiot (Tokyo); 1981 Sep; 34(9):1200-5. PubMed ID: 6173369
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A.
Schaefer A; Boldt J; Westendorf J; Steinheider G; Marquardt H
Biochem Pharmacol; 1988 Apr; 37(7):1377-82. PubMed ID: 3162677
[TBL] [Abstract][Full Text] [Related]
11. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin.
Kunimoto S; Miura K; Takahashi Y; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1983 Mar; 36(3):312-7. PubMed ID: 6833151
[TBL] [Abstract][Full Text] [Related]
12. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
13. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells.
Long BH; Willis CE; Prestayko AW; Crooke ST
Mol Pharmacol; 1982 Jul; 22(1):152-7. PubMed ID: 6956804
[TBL] [Abstract][Full Text] [Related]
14. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part I - Antitumor antibiotics and their derivatives.
Umezawa H
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):12-8. PubMed ID: 6173340
[TBL] [Abstract][Full Text] [Related]
15. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.
Sugimoto Y; Hirakawa Y; Tanaka N; Tahara M; Sato I; Nishimura T; Suzuki H; Tanaka N
Cancer Res; 1986 Nov; 46(11):5646-8. PubMed ID: 3463416
[TBL] [Abstract][Full Text] [Related]
16. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
Burres NS; Myers MT; Sartorelli AC
Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
[TBL] [Abstract][Full Text] [Related]
17. Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.
Inaba M; Johnson RK
Biochem Pharmacol; 1978; 27(17):2123-30. PubMed ID: 31880
[No Abstract] [Full Text] [Related]
18. Cellular accumulation and disposition of aclacinomycin A.
Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
Zenebergh A; Baurain R; Trouet A
Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
[TBL] [Abstract][Full Text] [Related]
20. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
